[Featured Stock] Surge in Biosimilar-Related Stocks... Isu Abxis Hits Upper Limit

[Asia Economy Reporter Ji Yeon-jin] Bio-pharmaceutical company Isu Abxis surged to the upper price limit on the 15th.

Isu Abxis traded at 14,150 KRW, up 29.82%, around 9:13 AM and has maintained the price since then.

This is interpreted as a result of biosimilar developers showing strength following Celltrion's announcement of the European-wide sales approval of Humira biosimilar Uplyma (CT-P17), a rheumatoid arthritis treatment. Celltrion traded at 335,000 KRW in the morning, rising only 0.90% compared to the previous session.